Chewy sales, margins improve but GAAP profit dips after prior tax benefit; buybacks roll on

Chewy, Inc. (NYSE: CHWY) - quick read on what's happening inside

High-level summary:
* Chewy grew net sales but earned materially less net income than last year due to a large prior‑year deferred tax benefit. The company is investing in fulfillment, pharmacy and software while continuing an active share repurchase program.

Snapshot - key facts & figures (as reported)
* Net sales: $3,104.2 million (13 weeks ended Aug 3, 2025) and $6,220.2 million (26 weeks ended Aug 3, 2025).
* Net income: $62.0 million (13 weeks) and $124.4 million (26 weeks) vs $299.1 million and $366.0 million in the prior-year periods.
* Gross profit: $942.2 million (13 weeks); gross margin 30.4% (13 weeks) and 30.0% (26 weeks).
* Adjusted EBITDA: $183.3 million (13 weeks, +26.5% YoY); adjusted EBITDA margin 5.9% (13 weeks).
* Adjusted net income (non‑GAAP): $141.1 million (13 weeks, +34.8% YoY) and $290.0 million (26 weeks).
* Active customers: 20.906 million (up 4.5% YoY). Net sales per active customer: $591 (up 4.6% YoY).
* Autoship customer sales: $2,576.9 million (13 weeks, +14.9% YoY); Autoship as % of net sales 83.0% (13 weeks).
* Cash & cash equivalents: $591.8 million as of Aug 3, 2025.
* Inventories: $874.6 million (up from $836.7 million Feb 2, 2025).
* Trade accounts payable: $1,226.0 million; total current liabilities: $2,193.2 million.
* Net cash provided by operating activities (26 weeks): $220.3 million; free cash flow (26 weeks): $154.6 million.
* Share repurchases: $152.6 million (cash outflow in financing activities for the 26‑week period); remaining Repurchase Program authorization ≈ $359.8 million.
* Borrowing capacity under ABL Credit Facility: $782.8 million; no outstanding borrowings as of Aug 3, 2025.
* Weighted‑average diluted shares (26 weeks): 426.8 million; diluted EPS (26 weeks): $0.29.

What's happening inside - operations & corporate moves
* Execution: continued investment in fulfillment (Houston expansion), pharmacy fulfillment network and veterinary clinics; capital expenditures $65.7 million (26 weeks).
* Technology: finance IT modernization project underway to improve reporting and analytics; company says minimal capital required for that project.
* Capital allocation: active share repurchase activity (including a $100 million concurrent repurchase tied to a June 2025 secondary offering by a selling holder).
* Ownership/governance: BC Partners and affiliates control majority voting power (company is a "controlled company").

Income statement - positives
* Top‑line growth: net sales +8.6% (13 weeks) and +8.4% (26 weeks) YoY, driven by Autoship growth (+14.9% / +14.8%).
* Margin improvement: gross margin improved to 30.4% (13 weeks) from 29.5% - aided by Autoship mix, sponsored ads and margin gains in consumables & healthcare.
* Operating leverage: income from operations rose to $69.7 million (13 weeks) from $32.1 million, aided by higher sales vs. SG&A growth.
* Cash generation: operating cash flow $220.3 million (26 weeks) and positive free cash flow $154.6 million (26 weeks).

Income statement - negatives / risks
* Net income compression: large YoY decline in GAAP net income (13 weeks: $62.0M vs $299.1M prior) - primarily because last year included a $275.7M deferred tax valuation allowance release that produced a big tax benefit.
* Net margin fell to 2.0% (13 weeks) from 10.5% prior year; income tax provision $27.5M year‑to‑date vs a significant benefit in prior year.
* Lower investment income: interest and other income, net declined materially (interest income reduced as marketable securities matured last year), decreasing reported other income.
* High non‑cash share‑based comp: $150.4 million YTD; dilutive potential - diluted shares ~426.8M (26 weeks).
* Working capital pressure and inventory level: inventories $874.6M and trade payables large at $1,226.0M - elevated inventory is execution risk if demand weakens.
* Current liabilities heavy: total current liabilities $2,193.2M vs current assets $1,781.9M - tight near‑term balance sheet composition to monitor.
* Legal/contingency language: company maintains accruals but notes litigation and indemnities - and BC Partners indemnification arrangements tied to prior Transactions (tax indemnities).

Analyst takeaways - be straight
* Growth quality: organic customer metrics look healthy - active customers +4.5% and Autoship growth strong. That supports recurring revenue and margin stability.
* Earnings caution: GAAP net income is suppressed vs. prior year because of a one‑time tax benefit a year ago. Adjusted metrics (Adjusted EBITDA, adjusted net income) show operational improvement, but investors must accept non‑GAAP adjustments (notably big share‑based comp).
* Liquidity & capital allocation: cash ~$592M, healthy ABL capacity, steady FCF - company is comfortable repurchasing shares while investing in fulfillment/pharmacy. Watch inventory and payable cycles and continued capital discipline.
* Key risks: inventory buildup, reduced interest income, significant share‑based compensation dilution, and dependency on Autoship retention and shipping costs.

Bottom line: Chewy is growing sales and improving gross margins while investing in the business and returning capital via repurchases. GAAP net income is lower compared with the prior year because the prior period benefited from a large deferred tax valuation release; operational profitability and cash flow metrics show progress but inventory, high current liabilities and recurring share‑based compensation are items to watch closely.

If you want, I can:
* Pull a one‑page P&L vs prior quarters with percent changes.
* Create an alerts summary for upcoming catalysts (repurchase status, tax and legal notes, earnings drivers).